Global Veterinary Oncology Market (2023-2028) Competitive Analysis, Impact of Covid-19, Ansoff Analysis

The Global Veterinary Oncology Market is estimated to be USD 75.08 Mn in 2023 and is expected to reach USD 107.84 Mn by 2028 growing at a CAGR of 7.51%.

Market Dynamics

The key factors driving the growth of this market include upsurge in the prevalence of cancer in pets, increasing research and investments in pet cancer, growing focus on animal safety whereas high cost associated with chemotherapies, immunotherapies, and targeted therapies are major factors restraining the veterinary oncology market growth.

Market Segmentation

• The Global Veterinary Oncology Market is segmented further based on Type, Animal Type, Therapy and Geography.
• By Type, the market is classified into Lymphoma, mast cell cancer, mammary and squamous cell cancer, others like anal sac carcinoma. Rising incidence of mast cell cancer in dogs is further expected to drive the market growth.
• By Animal Type, the market is classified into Companion Animal or Livestock Animal.
• By Therapy, the market is classified into Chemotherapy, Combination Therapy, Immunotherapy and Targeted Therapy. Chemotherapy has progressed dramatically with canine oncology.
• By Geography, North America is projected to dominate the market over the forecast period.

Recent Developments

1. Boehringer Ingelheim took over AMAL Therapeutics, a biotechnology company focused on cancer immunotherapy. The acquisition helped the company to become an innovator of novel cancer therapies, including immuno-oncology treatments. July 2019.
2. Elanco acquired Aratana Therapeutics in April 2019, after which, the company declared the formation of a commercial team devoted to the veterinary specialty business.
3. Another contribution by the market player in August 2019, was the initiation of Phase 2 clinical trial by PharmAust in Australia with its leading veterinary drug candidate, monepantel, to treat canine cancer.

Company Profiles

Some of the companies covered in this report are Boehringer Ingelheim International GmbH, Karyopharm Therapeutics, Inc., Regeneus Ltd., Elanco Animal Health, Inc., Zoetis, Inc., Varian Medical Systems, Inc., PetCure Oncology, LLC (Accelitech, LLC), AB Science SA, Rhizen Pharmaceuticals S.A., and Nippon Zenyaku Kogyo Co., Ltd., etc.

Competitive Quadrant

The report includes Competitive Quadrant, a proprietary tool to analyze and evaluate the position of companies based on their Industry Position score and Market Performance score. The tool uses various factors for categorizing the players into four categories. Some of these factors considered for analysis are financial performance over the last 3 years, growth strategies, innovation score, new product launches, investments, growth in market share, etc.

Why buy this report?

• The report offers a comprehensive evaluation of the Global Veterinary Oncology Market. The report includes in-depth qualitative analysis, verifiable data from authentic sources, and projections about market size. The projections are calculated using proven research methodologies.
• The report has been compiled through extensive primary and secondary research. The primary research is done through interviews, surveys, and observation of renowned personnel in the industry.
• The report includes in-depth market analysis using Porter’s 5 force model and the Ansoff Matrix. The impact of Covid-19 on the market is also featured in the report.
• The report also contains the competitive analysis using Competitive Quadrant, the proprietary competitive positioning tool.

Report Highlights:

• A complete analysis of the market, including parent industry
• Important market dynamics and trends
• Market segmentation
• Historical, current, and projected size of the market based on value and volume
• Market shares and strategies of key players
• Recommendations to companies for strengthening their foothold in the market